| 000 | 01636 a2200493 4500 | ||
|---|---|---|---|
| 005 | 20250513202330.0 | ||
| 264 | 0 | _c20000229 | |
| 008 | 200002s 0 0 eng d | ||
| 022 | _a0960-8931 | ||
| 024 | 7 |
_a10.1097/00008390-199912000-00011 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aCure, H | |
| 245 | 0 | 0 |
_aResults of a phase II trial with cystemustine at 90 mg/m(2) as a first- or second-line treatment in advanced malignant melanoma: a trial of the EORTC Clinical Studies Group. _h[electronic resource] |
| 260 |
_bMelanoma research _cDec 1999 |
||
| 300 |
_a607-10 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial; Clinical Trial, Phase II; Journal Article | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aAntineoplastic Agents _xadministration & dosage |
| 650 | 0 | 4 | _aCombined Modality Therapy |
| 650 | 0 | 4 |
_aDacarbazine _xtherapeutic use |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aImmunotherapy |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aMelanoma _xdrug therapy |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aNeoplasm Staging |
| 650 | 0 | 4 |
_aNitrosourea Compounds _xadministration & dosage |
| 650 | 0 | 4 | _aTreatment Outcome |
| 700 | 1 | _aSouteyrand, P | |
| 700 | 1 | _aOuabdesselam, R | |
| 700 | 1 | _aRoche, H | |
| 700 | 1 | _aRavaud, A | |
| 700 | 1 | _aD'incan, M | |
| 700 | 1 | _aViens, P | |
| 700 | 1 | _aFargeot, P | |
| 700 | 1 | _aLentz, M A | |
| 700 | 1 | _aFumoleau, P | |
| 700 | 1 | _aHanauske, A | |
| 700 | 1 | _aChollet, P | |
| 773 | 0 |
_tMelanoma research _gvol. 9 _gno. 6 _gp. 607-10 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1097/00008390-199912000-00011 _zAvailable from publisher's website |
| 999 |
_c10616684 _d10616684 |
||